- The Washington Times - Monday, January 26, 2009

NEW YORK (AP) — Pharmaceutical giant Pfizer Inc. is buying rival drugmaker Wyeth in a $68 billion cash-and-stock deal that could reshape the drug development industry.

Pfizer also says its net income for the fourth quarter dropped 90% from a year ago, hurt by a charge to resolve investigations into off-label promotional practices. It also plans to cut its work force by about 10 percent, and reduce the number of manufacturing sites.

New York-based Pfizer says it will pay $50.19 per share under the deal with Wyeth, valuing Madison, N.J.-based Wyeth at a 14.7 percent premium to the company’s closing price of $43.74 Friday. Both companies’ boards of directors approved the deal.

Pfizer says the deal is expected to add to the company’s fourth-quarter adjusted profit. It expects to close the deal during the third or fourth quarter.

Copyright © 2018 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.


Click to Read More

Click to Hide